Symbol="ACRS"
AssetType="Common Stock"
Name="Aclaris Therapeutics Inc"
Description="Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company is headquartered in Wayne, Pennsylvania."
CIK="1557746"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="SUITE 400, 101 LINDENWOOD DRIVE, MALVERN, PA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="638235000"
EBITDA="-84357000"
PERatio="None"
PEGRatio="-0.13"
BookValue="2.631"
DividendPerShare="0"
DividendYield="0"
EPS="-1.33"
RevenuePerShareTTM="0.463"
ProfitMargin="0"
OperatingMarginTTM="-3.107"
ReturnOnAssetsTTM="-0.262"
ReturnOnEquityTTM="-0.539"
RevenueTTM="30827000"
GrossProfitTTM="-60021000"
DilutedEPSTTM="-1.33"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.74"
AnalystTargetPrice="29.13"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="43.63"
PriceToBookRatio="4.905"
EVToRevenue="35.36"
EVToEBITDA="-10.0"
Beta="0.604"
num_52WeekHigh="18.96"
num_52WeekLow="5.77"
num_50DayMovingAverage="9.87"
num_200DayMovingAverage="12.13"
SharesOutstanding="70679000"
DividendDate="None"
ExDividendDate="None"
symbol="ACRS"
open="9.11"
high="9.37"
low="8.65"
price="8.66"
volume="554996.00"
latest_trading_day="2023-08-08"
previous_close="9.14"
change="-0.48"
change_percent="-5.2516%"
aroon_positive_momentum_days="48"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="48"
Volume_recent_avg="638560"
Change_recent_avg="0.01"
Delta_recent_avg="0.45"
Variance_recent_avg="0.23"
Change_ratio_recent_avg="0.03"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="48"
Aroon_momentum_negative="52"
image_negative_thumbnail_id_1="1152"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0185.jpeg"
image_negative_thumbnail_id_2="163"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0013.jpeg"
image_neutral_thumbnail_id_1="586"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0013.jpeg"
image_neutral_thumbnail_id_2="568"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0031.jpeg"
image_positive_thumbnail_id_1="987"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0149.jpeg"
image_positive_thumbnail_id_2="634"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0074.jpeg"
image_professor_thumbnail_id_1="1169"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0003.jpeg"
image_professor_thumbnail_id_2="1174"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
